{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T06:03:10Z","timestamp":1777960990799,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,10,5]],"date-time":"2013-10-05T00:00:00Z","timestamp":1380931200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s11255-013-0551-7","type":"journal-article","created":{"date-parts":[[2013,10,4]],"date-time":"2013-10-04T06:55:25Z","timestamp":1380869725000},"page":"523-529","source":"Crossref","is-referenced-by-count":23,"title":["Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study"],"prefix":"10.1007","volume":"46","author":[{"given":"Seung Hwan","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Soo","family":"Byun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khae Hawn","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Youl","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,5]]},"reference":[{"key":"551_CR1","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1464-410X.2008.07717.x","volume":"102","author":"M Emberton","year":"2008","unstructured":"Emberton M, Fitzpatrick JM, Garcia-Losa M et al (2008) Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU Int 102:981\u2013986","journal-title":"BJU Int"},{"key":"551_CR2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0022-5347(01)65075-4","volume":"157","author":"TJ Peters","year":"1997","unstructured":"Peters TJ, Donovan JL, Kay HE et al (1997) The International Continence Society \u201cbenign prostatic hyperplasia\u201d study: the bothersomeness of urinary symptoms. J Urol 157:885\u2013889","journal-title":"J Urol"},{"key":"551_CR3","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/ncpuro0754","volume":"4","author":"GE Lemack","year":"2007","unstructured":"Lemack GE (2007) Defining the role of overactive bladder treatments in men with lower urinary tract symptoms. Nat Clin Pract Urol 4:174\u2013175","journal-title":"Nat Clin Pract Urol"},{"key":"551_CR4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","volume":"54","author":"CR Chapple","year":"2008","unstructured":"Chapple CR, Khullar V, Gabriel Z et al (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54:543\u2013562","journal-title":"Eur Urol"},{"key":"551_CR5","doi-asserted-by":"crossref","unstructured":"Kaplan SA, Walmsley K, Te AE et al. (2005) Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174: 2273\u20132275 discussion 2275\u20132276","DOI":"10.1097\/01.ju.0000181823.33224.a0"},{"key":"551_CR6","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1464-410X.2006.06016.x","volume":"97","author":"BH Chung","year":"2006","unstructured":"Chung BH, Hong SJ, Cho JS et al (2006) Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study. BJU Int 97:742\u2013746","journal-title":"BJU Int"},{"key":"551_CR7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000019529","volume":"33","author":"E Lee","year":"1998","unstructured":"Lee E, Yoo KY, Kim Y et al (1998) Prevalence of lower urinary tract symptoms in Korean men in a community-based study. Eur Urol 33:17\u201321","journal-title":"Eur Urol"},{"key":"551_CR8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.juro.2007.03.133","volume":"178","author":"JG Blaivas","year":"2007","unstructured":"Blaivas JG, Panagopoulos G, Weiss JP et al (2007) Validation of the overactive bladder symptom score. J Urol 178:543","journal-title":"J Urol"},{"key":"551_CR9","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.eururo.2006.01.007","volume":"49","author":"KS Coyne","year":"2006","unstructured":"Coyne KS, Matza LS, Kopp Z et al (2006) The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 49:1079\u20131086","journal-title":"Eur Urol"},{"key":"551_CR10","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1442-2042.2005.01066.x","volume":"12","author":"M Takei","year":"2005","unstructured":"Takei M, Homma Y, Japanese Tolterodine Study Group (2005) Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. Int J Urol 12:456\u2013464","journal-title":"Int J Urol"},{"key":"551_CR11","doi-asserted-by":"crossref","unstructured":"Roehrborn CG, Kaplan SA, Kraus SR et al (2008) Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology 72: 1061\u20131067 discussion 1067","DOI":"10.1016\/j.urology.2008.06.067"},{"key":"551_CR12","doi-asserted-by":"crossref","unstructured":"Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50: 1306\u20131314 discussion 1314\u20131315","DOI":"10.1016\/j.eururo.2006.09.019"},{"key":"551_CR13","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","volume":"296","author":"SA Kaplan","year":"2006","unstructured":"Kaplan SA, Roehrborn CG, Rovner ES et al (2006) Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296:2319\u20132328","journal-title":"JAMA"},{"key":"551_CR14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.eururo.2012.07.003","volume":"63","author":"SA Kaplan","year":"2012","unstructured":"Kaplan SA, He W, Koltun WD et al (2012) Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. Eur Urol 63:158\u2013165","journal-title":"Eur Urol"},{"key":"551_CR15","doi-asserted-by":"crossref","unstructured":"Abrams P, Kaplan S, De Koning Gans HJ et al (2006) Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175: 999\u20131004","DOI":"10.1016\/S0022-5347(05)00483-0"},{"key":"551_CR16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1464-410X.1997.00380.x","volume":"80","author":"P Abrams","year":"1997","unstructured":"Abrams P, Speakman M, Stott M et al (1997) A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 80:587\u2013596","journal-title":"Br J Urol"},{"key":"551_CR17","first-page":"56","volume":"124","author":"YH Sun","year":"2011","unstructured":"Sun YH, Liu ZY, Zhang ZS et al (2011) Long-term efficacy and safety of tamsulosin hydrochloride for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: data from China. Chin Med J 124:56\u201360","journal-title":"Chin Med J"},{"key":"551_CR18","first-page":"301","volume":"23","author":"A Tsujimura","year":"2010","unstructured":"Tsujimura A, Takao T, Okuda H et al (2010) Survey of lower urinary tract symptoms in patients with benign prostatic hyperplasia and usefulness of tamsulosin hydrochloride. Jpn J Urol Surg 23:301\u2013308","journal-title":"Jpn J Urol Surg"},{"key":"551_CR19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(03)00622-7","volume":"3","author":"KE Andersson","year":"2004","unstructured":"Andersson KE (2004) Antimuscarinics for the treatment of overactive bladder. Lancet Neurol 3:46\u201353","journal-title":"Lancet Neurol"},{"key":"551_CR20","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/sj.bjp.0703475","volume":"130","author":"EA Szell","year":"2000","unstructured":"Szell EA, Yamamoto T, de Groat WC, Somogyi GT (2000) Smooth muscle and parasympathetic nerve terminals in the rat urinary bladder have different subtypes of alpha(1) adrenoceptors. Br J Pharmacol 130:1685\u20131691","journal-title":"Br J Pharmacol"},{"key":"551_CR21","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0022-5347(05)00708-1","volume":"175","author":"ED Crawford","year":"2006","unstructured":"Crawford ED, Wilson SS, McConnell JD et al (2006) Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 175:1422\u20131427","journal-title":"J Urol"},{"key":"551_CR22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.juro.2008.03.027","volume":"180","author":"SA Kaplan","year":"2008","unstructured":"Kaplan SA, Wein AJ, Staskin DR et al (2008) Urinary retention and post-void residual urine in men: separating truth from tradition. J Urol 180:47\u201354","journal-title":"J Urol"},{"key":"551_CR23","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.urology.2011.02.055","volume":"78","author":"O Yamaguchi","year":"2011","unstructured":"Yamaguchi O, Kakizaki H, Homma Y et al (2011) Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms\u2014ASSIST, randomized controlled study. Urology 78:126\u2013133","journal-title":"Urology"},{"key":"551_CR24","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.juro.2009.08.023","volume":"182","author":"SA Kaplan","year":"2009","unstructured":"Kaplan SA, McCammon K, Fincher R et al (2009) Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol 182:2825\u20132830","journal-title":"J Urol"},{"key":"551_CR25","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1001\/jama.280.23.1995","volume":"280","author":"KL Burgio","year":"1998","unstructured":"Burgio KL, Locher JL, Goode PS et al (1998) Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 280:1995\u20132000","journal-title":"JAMA"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-013-0551-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-013-0551-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-013-0551-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,28]],"date-time":"2019-07-28T21:48:23Z","timestamp":1564350503000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-013-0551-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,5]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["551"],"URL":"https:\/\/doi.org\/10.1007\/s11255-013-0551-7","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,5]]}}}